Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Loretta J. Nastoupil"'
Autor:
Loretta J. Nastoupil, Collin K. Chin, Jason R. Westin, Nathan H. Fowler, Felipe Samaniego, Xiaoyun Cheng, Man Chun John Ma, Zhiqiang Wang, Fuliang Chu, Ly Dsouza, Chizobam Obi, Jennifer Mims, Lei Feng, Shouhao Zhou, Michael Green, Richard Eric Davis, Sattva S. Neelapu
Publikováno v:
Blood Advances. 6:1143-1151
PD-1 blockade enhances the function of antitumor T cells and antibody-dependent, cell-mediated cytotoxicity (ADCC) of NK cells. In a single-center, open-label, phase 2 trial, we tested the combination of pembrolizumab, an anti-PD-1 monoclonal antibod
Autor:
Matthew A. Lunning, Hari P. Miskin, Jonathon B. Cohen, Nathan Fowler, Marshall T. Schreeder, Tanya Siddiqi, Loretta J. Nastoupil, Michael S. Weiss, Jan A. Burger, Christopher R. Flowers, Susan O'Brien, Julie M. Vose, Peter Sportelli, William G. Wierda
Publikováno v:
Blood
Targeting both CD20 and phosphatidylinositol 3-kinase (PI3K), a protein that is critically involved in B-cell maturation, could be an efficacious strategy for treating B-cell malignancies. The safety of the next-generation compounds umbralisib, a PI3
Autor:
Sattva S. Neelapu, Ann S. LaCasce, Jason R. Westin, C. David Fuller, Zeinab Abou Yehia, Hubert H. Chuang, L. Jeffrey Medeiros, Philippe Armand, Bouthaina S. Dabaja, Christine F. Wogan, Wei Qiao, Jillian R. Gunther, Yasuhiro Oki, William Martin-Doyle, Michelle A. Fanale, Andrea K. Ng, Grace L. Smith, Loretta J. Nastoupil, Mani Akhtari, Chelsea C. Pinnix, Sarah A. Milgrom, Osama Mawlawi
Publikováno v:
Blood Advances. 2:1334-1343
Dose-adjusted rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-R-EPOCH) has produced good outcomes in primary mediastinal B-cell lymphoma (PMBCL), but predictors of resistance to this treatment are unclear. We
Autor:
Nathan Fowler, Ethan B. Ludmir, Raphael E Steiner, Swaminathan P. Iyer, Chan Yoon Cheah, Sattva S. Neelapu, Luis Fayad, Jason R. Westin, Michael L. Wang, Christine F. Wogan, Jillian R. Gunther, Maria Alma Rodriguez, Loretta J. Nastoupil, Felipe Samaniego, L. Jeffrey Medeiros, Amy Rich, Bouthaina S. Dabaja, Sarah A. Milgrom, Chelsea C. Pinnix, Hun J. Lee
Radiation fields for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) have shrunk over time; involved-site radiation therapy (ISRT) has replaced extended-field radiation therapy (EFRT) and involved-field radiation therapy (IFRT),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6f7d26e3f1798b97f6d1f1ccf1ce674
https://europepmc.org/articles/PMC6517662/
https://europepmc.org/articles/PMC6517662/